Urology · Portland, OR
NPI
1225328958
Since 2011
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
5050 NE Hoyt St Ste 514
Portland, OR, 97213
Phone (503) 488-2323
Groups this clinician bills Medicare through
Medicare paid, 2024
$173K
8,385 services
Medicare patients, 2024
406
Average age 74
Drug cost, 2024
$165K
1,842 prescriptions
Company payments, 2025
$212
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Amanda A Vandlac was code J0585 (injection, onabotulinumtoxina, 1 unit), 3,500 times for 20 patients. In total Amanda A Vandlac billed 8,385 services in 92 codes, and Medicare paid $173K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-03-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 3,500 | 20 | $4.98 | $17K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 1,825 | 14 | $0.11 | $198 |
| J9030 Bcg live intravesical instillation, 1 mg | Office | 1,150 | 12 | $2.28 | $2,620 |
| 99214 Office E&M - Established | Office | 170 | 137 | $93.73 | $16K |
| 81003 Clinical Chemistry | Office | 151 | 128 | $2.20 | $332 |
| 51798 Ultrasound - Nonspecific | Office | 132 | 113 | $8.41 | $1,110 |
| 99204 Office E&M - New | Office | 129 | 129 | $112.42 | $15K |
| 52000 Cystourethroscopy | Office | 94 | 78 | $181.27 | $17K |
| 99213 Office E&M - Established | Office | 71 | 66 | $63.98 | $4,543 |
| 51705 Other Organ Systems | Office | 31 | 17 | $59.39 | $1,841 |
| 99215 Office E&M - Established | Office | 28 | 25 | $135.13 | $3,784 |
| 81002 Clinical Chemistry | Office | 27 | 25 | $3.41 | $92.07 |
| 52310 Calculus Removal - Urinary | Office | 25 | 22 | $255.79 | $6,395 |
| 76872 Ultrasound - Nonspecific | Office | 25 | 25 | $112.48 | $2,812 |
| 52287 Cystourethroscopy | Office | 25 | 20 | $299.65 | $7,491 |
By year: 2022 $114K for 4,178 services; 2023 $182K for 6,317 services; 2024 $173K for 8,385 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 151 | 128 | $2.20 | $332 |
| 81002 Clinical Chemistry | 27 | 25 | $3.41 | $92.07 |
Medicare prescription drug claims, 2024
In 2024, the drug Amanda A Vandlac prescribed most often to Medicare patients was Tolterodine Tartrate Er (Tolterodine Tartrate), with 455 prescriptions and refills. In total Amanda A Vandlac wrote 1,842 Medicare prescriptions that cost $165K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tolterodine Tartrate Er Tolterodine Tartrate | 455 | 658 | 120 | $26K |
| Tamsulosin Hcl Generic | 403 | 784 | 130 | $5,460 |
| Finasteride Generic | 187 | 394 | 54 | $1,939 |
| Myrbetriq Mirabegron | 152 | 192 | 39 | $82K |
| Solifenacin Succinate Generic | 114 | 173 | 29 | $2,567 |
| Oxycodone Hcl Generic | 90 | 90 | 79 | $329 |
| Tadalafil Generic | 54 | 84 | 13 | $672 |
| Cephalexin Generic | 49 | 69 | 24 | $470 |
| Oxybutynin Chloride Generic | 41 | 43 | 38 | $255 |
| Ciprofloxacin Hcl Generic | 30 | 30 | 30 | $188 |
| Estradiol Generic | 28 | 95 | 17 | $2,237 |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 27 | 29 | 25 | $498 |
| Trospium Chloride Generic | 26 | 34 | Under 11 | $1,659 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 24 | 30 | 21 | $215 |
| Tolterodine Tartrate Generic | 23 | 36 | Under 11 | $1,909 |
Brand drugs: 189 claims; generic drugs: 1,653 claims; opioid claims: 96.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Amanda A Vandlac $212 ($212 in general payments such as food, travel and fees) from 5 companies. The largest payer was Janssen Biotech, Inc. with $68.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.